SANTA CRUZ BIOTECHNOLOGY, INC.

KIR3.2 (E-17): sc-139517

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

The smallest of the human chromosomes, 21, makes up about 1.5% of the human genome. Chromosome 21 contains nearly 300 genes and 47 million base pairs. Down syndrome, also known as trisomy 21, is the disease most commonly associated with chromosome 21. Alzheimer's disease, Jervell and Lange-Nielsen syndrome and amyotrophic lateral sclerosis are also associated with chromosome 21. Translocations are found to occur between chromosome 21 and 8, and chromosome 21 and 12 in certain leukemias. The KIR3.2 gene product has been provisionally designated KIR3.2 pending further characterization.

REFERENCES

1. Tesson, F., Donger, C., Denjoy, I., Berthet, M., Bennaceur, M., Petit, C., Coumel, P., Schwarts, K. and Guicheney, P. 1996. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J. Mol. Cell. Cardiol. 28: 2051-2055.
2. Tyson, J., Tranebjaerg, L., Bellman, S., Wren, C., Taylor, J.F., Bathen, J., Aslaksen, B., Sørland, S.J., Lund, O., Malcolm, S., Pembrey, M., Bhattacharya, S. and Bitner-Glindzicz, M. 1997. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum. Mol. Genet. 6: 2179-2185.
3. Müller, S., Stanyon, R., Finelli, P., Archidiacono, N. and Wienberg, J. 2000. Molecular cytogenetic dissection of human chromosomes 3 and 21 evolution. Proc. Natl. Acad. Sci. USA 97: 206-211.
4. Mao, R., Wang, X., Spitznagel, E.L.Jr., Frelin, L.P., Ting, J.C., Ding, H., Kim, J.W., Ruczinski, I., Downey, T.J. and Pevsner, J. 2005. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol. 6: R107.
5. Robakis, N.K. 2006. The discovery and mapping to chromosome 21 of the Alzheimer's amyloid gene: history revised. J. Alzheimers Dis. 10: 453-455.
6. Sun, X., He, G. and Song, W. 2006. BACE2, as a novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 20: 1369-1376.
7. Aït Yahya-Graison, E., Aubert, J., Dauphinot, L., Rivals, I., Prieur, M., Golfier, G., Rossier, J., Personnaz, L., Creau, N., Bléhaut, H., Robin, S., Delabar, J.M. and Potier, M.C. 2007. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 81: 475-491.
8. Peterson, L.F., Boyapati, A., Ahn, E.Y., Biggs, J.R., Okumura, A.J., Lo, M.C., Yan, M. and Zhang, D.E. 2007. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 110: 799-805.
9. Ryoo, S.R., Jeong, H.K., Radnaabazar, C., Yoo, J.J., Cho, H.J., Lee, H.W., Kim, I.S., Cheon, Y.H., Ahn, Y.S., Chung, S.H. and Song, W.J. 2007. DYRK1A-mediated Hyperphosphorylation of Tau: A functional link between Down syndrome and Alzheimer's disease. J. Biol. Chem. 282: 34850-34857.

CHROMOSOMAL LOCATION

Genetic locus: KCNJ6 (human) mapping to 21q22.13; Kcnj6 (mouse) mapping to 16 C4.

SOURCE

KIR3.2 (E-17) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within a C-terminal cytoplasmic domain of KIR3.2 of human origin.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-139517 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

KIR3.2 (E-17) is recommended for detection of KIR3.2 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:50-1:500), immunofluorescence (starting dilution 1:25, dilution range 1:25-1:250) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with KIR3.1, KIR3.3 or KIR3.4.

KIR3.2 (E-17) is also recommended for detection of KIR3.2 in additional species, including canine, bovine and avian.

Suitable for use as control antibody for KIR3.2 siRNA (h): sc-42618, KIR3.2 siRNA (m): sc-42619, KIR3.2 shRNA Plasmid (h): sc-42618-SH, KIR3.2 shRNA Plasmid (m): sc-42619-SH, KIR3.2 shRNA (h) Lentiviral Particles: sc-42618-V and KIR3.2 shRNA (m) Lentiviral Particles: sc-42619-V.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.